0000000000514306

AUTHOR

E. D'amico

showing 5 related works from this author

Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a…

2020

Background Accurate and up-to-date assessment of demographic metrics is crucial for understanding a wide range of social, economic, and public health issues that affect populations worldwide. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 produced updated and comprehensive demographic assessments of the key indicators of fertility, mortality, migration, and population for 204 countries and territories and selected subnational locations from 1950 to 2019. Methods 8078 country-years of vital registration and sample registration data, 938 surveys, 349 censuses, and 238 other sources were identified and used to estimate age-specific fertility. Spatiotemporal Gaussian…

Malevery elderlyDemographic transitionHALE030204 cardiovascular system & hematologypreschool childGlobal Burden of DiseaseCarga Global de Enfermedades0302 clinical medicinenewbornRisk FactorsSurveys and Questionnairesand Risk Factors Study80 and over030212 general & internal medicineBirth RateChildMigration11 Medical and Health SciencesAged 80 and overeducation.field_of_studyInjuriesGeographyMortality rate1. No povertyDEATHCensusesGeneral MedicineSDG 10 - Reduced InequalitiesMiddle AgedDemographic analysis3142 Public health care science environmental and occupational health3. Good healthdemographic analysisEstilo de Vida SaludableGeographyrisk factorChild Preschool/dk/atira/pure/sustainabledevelopmentgoals/reduced_inequalitiesDemography/statistics & numerical dataGlobal Burden of Diseases Injuries Risk Factors Fertility Mortality Migration Population/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingepidemiologyFemaleA990 Medicine and Dentistry not elsewhere classifiedCHILD-MORTALITYLive BirthGlobal Health MetricsTRANSITIONdemographics ; GBD ; fertility ; mortality ; haleAdultAdolescentTotal fertility ratePopulationPopulation.Global Burden of Diseases Injuries and Risk Factors StudyBirth rate03 medical and health sciencesYoung AdultLife ExpectancySDG 3 - Good Health and Well-beingGeneral & Internal MedicineSYSTEMATIC ANALYSISDemografíaHumansGlobal Burden of Disease StudyhumanMortalityeducationPreschoolAgedDemographySpatial AnalysisquestionnaireInfant NewbornKlinisk medicinHIVInfantGlobal Burden of Diseasessex-specific fertilityMortality rateLive Birth/epidemiology//purl.org/pe-repo/ocde/ford#3.02.00 [https].Global Burden of DiseasesMODELFertilidadFertilityDemographic changeLife expectancyNAglobal disease burdenClinical Medicinepopulation researchDemographyThe Lancet
researchProduct

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

2009

OBJECTIVE: Recent findings support greater efficacy of early vs. delayed interferon beta (IFNbeta) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFNbeta treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFNbeta treatment with regard to the greatest benefits on disability progression. METHODS: A cohort of 2,570 IFNbeta-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients wit…

AdultMaleTime FactorsMultiple Sclerosis; Interferon betaInterferon-beta.Interferon betaCohort StudiesYoung AdultMultiple Sclerosis Relapsing-RemittingTreatment Outcomeobservational study multiple sclerosis interferon treatment earlySickness Impact ProfileMultiple SclerosiQuality of LifeHumansFemaleSettore MED/26 - NeurologiaProspective StudiesFollow-Up Studies
researchProduct

Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon bet…

2011

Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood. Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status. Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing–remitting MS treated with subcutaneous interferon beta-1a. Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 µg subcutaneously three times weekly, a…

AdultMaleQuality of lifeLongitudinal studymedicine.medical_specialtyInjections Subcutaneousmultiple sclerosisRelapsing-Remitting Multiple SclerosisInterferon beta 1aYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicQuality of lifeInternal medicinemedicineHumansYoung adultFatigueDepression (differential diagnoses)AgedDepressionbusiness.industryCognitive function; Depression; Fatigue; Interferon beta 1a; Longitudinal study; Quality of life; Relapsing-Remitting Multiple SclerosisMultiple sclerosisCognitive disorderInterferon beta-1aInterferon-betaMiddle Agedmedicine.diseaseClinical trialNeurologyPhysical therapymultiple sclerosis cognition interferon betaFemaleSettore MED/26 - NeurologiaCognitive functionNeurology (clinical)Longitudinal studyCognition DisordersbusinessInterferon beta-1amedicine.drugMultiple Sclerosis Journal
researchProduct

Five insights from the Global Burden of Disease Study 2019

2020

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a rules-based synthesis of the available evidence on levels and trends in health outcomes, a diverse set of risk factors, and health system responses. GBD 2019 covered 204 countries and territories, as well as first administrative level disaggregations for 22 countries, from 1990 to 2019. Because GBD is highly standardised and comprehensive, spanning both fatal and non-fatal outcomes, and uses a mutually exclusive and collectively exhaustive list of hierarchical disease and injury causes, the study provides a powerful basis for detailed and broad insights on global health trends and emerging challenges. GBD …

health care deliveryMaleHumans -- MalatiesOutcome Assessmentglobal healthDiseaseReviewinsights030204 cardiovascular system & hematologySocioeconomic FactorgeographyGlobal Burden of DiseaseNoncommunicable Diseasedisease burdenCarga Global de Enfermedades0302 clinical medicineRisk FactorsOutcome Assessment Health CareHealth careGlobal healthDelivery of health carehealth outcomesmiddle income countrybirth rate030212 general & internal medicineBirth Ratehealth outcomes health system responses economic developmentFactores de Riesgopublic healthhealth care costGeneral MedicineRisk factor (computing)humanities3. Good healthfemalepriority journalrisk factorhealth system responsesepidemiologyTERRITORIESpoliticsCLINICAL-TRIALSmedicine.medical_specialtyBirth Rate; Delivery of Health Care; Global Burden of Disease; Noncommunicable Diseases; Outcome Assessment Health Care; Risk Factors; Socioeconomic Factors; Wounds and Injuries; epidemiologyinjury2019195 COUNTRIESArticleGlobal Burden of Diseases health outcomes risk factors health system responsesHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]03 medical and health sciencessocioeconomicsmedicineSYSTEMATIC ANALYSISHumansGlobal Burden of Disease StudyhumanEpidemiologiaNoncommunicable DiseasesDisease burdenActuarial sciencehigh income countrybusiness.industryRisk FactorWounds and InjuriePublic healthagingHealth careeconomicsNon-communicable diseasemedicine.diseaseSalut públicaeconomic developmentEnfermedadesnon communicable disease//purl.org/pe-repo/ocde/ford#3.02.00 [https]Health CareRisk factorsSocioeconomic Factorspopulation growthLife expectancylife expectancyWounds and InjuriesNAPrestación de Atención de Saludglobal disease burdenbusinessDelivery of Health Carelow income country
researchProduct

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

2017

Background & Aims: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. Methods: Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N= 200) and w…

Male0301 basic medicinehepatitis C virusSustained Virologic ResponseSofosbuvirHepacivirusDrug ResistanceHepacivirusresistance-associated substitutionsViral Nonstructural ProteinsVARIANTSNS5Amedicine.disease_causeGastroenterologychemistry.chemical_compound0302 clinical medicineRecurrenceINFECTIONantiviral therapyMedicinehepatitis C viruViralTreatment FailureChronicantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutions; hepatologybiologyGENOTYPE 1virus diseasesMiddle Agedantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutionsSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCombinationInterferonDrug Therapy CombinationFemale030211 gastroenterology & hepatologyAuthor Keywords:antiviral therapyRIBAVIRINSequence AnalysisHumanmedicine.drugmedicine.medical_specialtyDaclatasvirGenotypeHepatitis C virusAntiviral AgentsLONG-TERM PERSISTENCEDACLATASVIR03 medical and health sciencesDrug Therapyantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutions; Aged; Antiviral Agents; Drug Resistance Viral; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferons; Italy; Male; Middle Aged; Mutation; Recurrence; Ribavirin; Sequence Analysis DNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins; HepatologyTREATMENT-NAIVEInternal medicineDrug Resistance ViralRibavirinHumansNS5Aresistance testdirect-acting antiviralsAgedAntiviral Agentresistance-associated substitutiondirect-acting antiviralHepaciviruHepatologyresistance test KeyWords Plus:HEPATITIS-C VIRUSbusiness.industryRibavirinViral Nonstructural ProteinSequence Analysis DNADNAHepatitis C ChronicHepatologybiology.organism_classificationClinical trial030104 developmental biologySOFOSBUVIRchemistrySequence AnalysihepatologyMutationImmunologyInterferonsSofosbuvirbusiness
researchProduct